Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NZUZJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Varsetatug masetecan
|
|||||
| Synonyms |
varsetatug masetecan; EpCAM-PDC; CX-2051; Varseta-M
Click to Show/Hide
|
|||||
| Organization |
CytomX Therapeutics (Originator);ImmunoGen (Top20 MNC)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Varsetatug
|
Antibody Info | ||||
| Antigen Name |
Epithelial cell adhesion molecule (EPCAM)
|
Antigen Info | ||||
| Payload Name |
CAMP59
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
L-ala-ala-ala (TAL)
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
masetecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|